Back to results

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Primary Purpose

Lung Cancer, Malignant Mesothelioma, Metastatic Cancer

Status

Completed

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

radiofrequency ablation

About this trial

This is an interventional treatment trial for Lung Cancer focused on measuring recurrent non-small cell lung cancer, recurrent small cell lung cancer, recurrent malignant mesothelioma, recurrent thymoma and thymic carcinoma, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, pulmonary carcinoid tumor, lung metastases

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of a primary or secondary intrathoracic malignancy Any cell type or origin Involving the intrapulmonary, mediastinal, or pleural/chest wall Inoperable primary or metastatic cancer to the lung Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy) Single or multiple lesions that are non-contiguous with vital structures or organs such as: Trachea Heart Aorta Great vessels Esophagus Less than 5 cm in largest dimension Accessible via percutaneous transthoracic route Hepatic: Coagulation profile normal

Sites / Locations

Jonsson Comprehensive Cancer Center, UCLA

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

NCT ID

NCT00024076

First Posted

September 13, 2001

Last Updated

July 30, 2020

Sponsor

Jonsson Comprehensive Cancer Center

1. Study Identification

Unique Protocol Identification Number

NCT00024076

Brief Title

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Official Title

Radiofrequency Ablation of Pulmonary Malignancy

Study Type

Interventional

2. Study Status

Record Verification Date

July 2012

Overall Recruitment Status

Completed

Study Start Date

May 2000 (undefined)

Primary Completion Date

December 2006 (Actual)

Study Completion Date

undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Jonsson Comprehensive Cancer Center

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Detailed Description

OBJECTIVES: Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies. Determine the efficacy of this treatment, in terms of local control, in these patients. Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients. OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours. Patients are followed at 1, 3, 6, and 12 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma

Keywords

recurrent non-small cell lung cancer, recurrent small cell lung cancer, recurrent malignant mesothelioma, recurrent thymoma and thymic carcinoma, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, pulmonary carcinoid tumor, lung metastases

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

30 (Actual)

8. Arms, Groups, and Interventions

Intervention Type

Procedure

Intervention Name(s)

radiofrequency ablation

10. Eligibility

Sex

All

Accepts Healthy Volunteers

Eligibility Criteria

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Robert D. Suh, MD

Organizational Affiliation

Jonsson Comprehensive Cancer Center

Official's Role

Study Chair

Facility Information:

Facility Name

Jonsson Comprehensive Cancer Center, UCLA

City

Los Angeles

State/Province

California

ZIP/Postal Code

90095-1781

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

We'll reach out to this number within 24 hrs